Ligand Pharmaceuticals LGND Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's operating cash flow?
- Ligand Pharmaceuticals (LGND) reported operating cash flow of $48.69M in Q1 2026.
- How has Ligand Pharmaceuticals's operating cash flow changed year-over-year?
- Ligand Pharmaceuticals's operating cash flow increased by 291.4% year-over-year, from -$25.45M to $48.69M.
- What is the long-term trend for Ligand Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's operating cash flow has grown at a -11.0% compound annual growth rate (CAGR), from $78.8M to $49.36M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.